Targeting iHSP 70 in vitiligo: a critical step for cure?

    loading  Checking for direct PDF access through Ovid


The group of Caroline Le Poole has produced a series of elegant papers suggesting an innovative rationale for the treatment of vitiligo by limiting native iHSP70 expression, with subsequent blockade of DC activation and melanocyte loss via T-cell-specific autoimmune responses. The proof of concept was made in a mouse model of the use of a mutant iHSP70 blunting this response. The comment emphasizes that in vitiligo, a skin and possibly epidermal defect underlies the initial steps leading to inflammation and subsequent melanocyte demise and discusses the relevance of targeting iHSP in this context.

Related Topics

    loading  Loading Related Articles